ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Early-stage research and discovery expense by Year
Early-stage research and discovery expense ($M) ($M)
Eli Lilly Early-stage research and discovery expense: $4,881M in FY2025, up 24.6% from a year earlier.
Latest, FY2025
4,881
Period ended Dec 31, 2025
Change on a year earlier
+24.6%
3,917 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-12) ↗
Reported in Form 10-Q / 10-K Segment Reporting Note (ASC 280-10-50-25A).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Early-stage research and discovery expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,881 | +24.6% | Form 10-K (filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 3,917 | +26.6% | Form 10-K (filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 3,093 | +28.5% | Form 10-K (filed 2026-02-12) ↗ |
| FY2022 | Dec 31, 2022 | 2,407 | – | Form 10-K (filed 2025-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Early-stage research and discovery expense ($M), annual FY2022–FY2025 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/rd-exp-early-stage
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.